trial

Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia

NCTId NCT03788759
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 48 (actual)
Sponsored by Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
Primary completion 2021-12-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
48 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2019-09-01
Primary completion
2021-12-01
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Alpha-lipoic acid

Sponsors

Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do CearaLead Sponsor
Conselho Nacional de Desenvolvimento Científico e TecnológicoCollaborator

Investigators

1
Lia LO Sanders, MD, PhDPrincipal Investigator

Sites

1 total
Fortaleza, Brazil

Linked catalysts

1
Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia — primary completion2021-12-01

Facts & assertions

4 sourced
Enrollment
48
Phase
PHASE2,PHASE3
Primary Completion Date
2021-12-01
Status
COMPLETED
relationships
The graph out of here
drug
Alpha-lipoic acid
drug
lead_sponsor
Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
company
collaborator
Conselho Nacional de Desenvolvimento Científico e Tecnológico
company
indication
Schizophrenia
indication
Schizophrenia
indication
Oxidative Stress
indication
investigator
Lia LO Sanders, MD, PhD
person